GenMark Diagnostics (NASDAQ: GNMK) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its competitors? We will compare GenMark Diagnostics to related businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Profitability

This table compares GenMark Diagnostics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GenMark Diagnostics -111.96% -109.89% -60.26%
GenMark Diagnostics Competitors -327.91% -35.29% -12.43%

Analyst Ratings

This is a summary of recent recommendations and price targets for GenMark Diagnostics and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GenMark Diagnostics 0 0 5 0 3.00
GenMark Diagnostics Competitors 252 1813 3249 105 2.59

GenMark Diagnostics currently has a consensus target price of $14.40, suggesting a potential upside of 56.86%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.11%. Given GenMark Diagnostics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe GenMark Diagnostics is more favorable than its competitors.

Institutional & Insider Ownership

53.0% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 7.5% of GenMark Diagnostics shares are owned by company insiders. Comparatively, 17.2% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

GenMark Diagnostics has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, GenMark Diagnostics’ competitors have a beta of 0.89, suggesting that their average share price is 11% less volatile than the S&P 500.

Earnings & Valuation

This table compares GenMark Diagnostics and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
GenMark Diagnostics $50.59 million -$49.93 million -7.59
GenMark Diagnostics Competitors $2.02 billion $430.74 million -71.64

GenMark Diagnostics’ competitors have higher revenue and earnings than GenMark Diagnostics. GenMark Diagnostics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

GenMark Diagnostics competitors beat GenMark Diagnostics on 7 of the 12 factors compared.

About GenMark Diagnostics

GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.